Drug: Daratumumab (Darzalex, Janssen)
Status: Approved in combination with pomalidomide (Pomalyst, Celgene) and dexamethasone for patients with multiple myeloma (MM) who have received ≥2 prior therapies, including lenalidomide (Revlimid, Celgene) and a proteasome inhibitor.
Significant Data:
- The approval was based on data from the Phase Ib EQUULEUS study, which showed that daratumumab resulted in an overall response rate of 59% (95% CI, 49.1-68.8) in combination with pomalidomide and